Phase III Clinical Trial to Evaluate the Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine，Recombinant (Hansenula Polymorpha)

NCT05916326 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

8000

Enrollment

INDUSTRY

Sponsor class

Conditions

Norovirus Infections
Norwalk Gastroenteritis

Interventions

BIOLOGICAL: Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine，Recombinant (Hansenula polymorpha)
BIOLOGICAL: placebo

Sponsor

National Vaccine and Serum Institute, China

Collaborators

[object Object]